Public Market Listing
Live quotes, historical charts, and market capitalization for Nippon Shinyaku are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
Fenfluramine(Fintepla) | Approved | Serotonin 5-HT2 receptorsSmall molecule | EpilepsyRett SyndromeDevelopmental and Epileptic EncephalopathiesDravet SyndromeLennox-Gastaut Syndrome |
Ferric derisomaltose(Monoferric / Monofer) | Approved | Iron repletionOther | Heart FailureChronic Kidney DiseaseIron Deficiency Anemia |
Tadalafil(Adcirca) | Approved | PDE5Small molecule | Pulmonary Arterial Hypertension |
| Approved | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase IISmall molecule | Acute Myeloid Leukemia | |
| Phase 3 | Iduronate-2-sulfatase (IDS)Gene therapy / editing | Mucopolysaccharidosis Type II | |
| Phase 3 | Cardiac cell therapyCell therapy | Heart FailureDuchenne Muscular Dystrophy |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
April 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (1)
April 2028 (1)
What to watch
2029 (1)
February 2029 (1)
What to watch
Regulatory and conference events
(14)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 13 past events are shown.
Financial reports
No financial reports recorded.